Ado-trastuzumab emtansine biosimilar (Jiangsu Hengrui Medicine)

N/A

Report date: 2025/03/13 08:46:16

Base Information

Drug NameAdo-trastuzumab emtansine biosimilar (Jiangsu Hengrui Medicine)
Drug Alias NameAdo-trastuzumab emtansine biosimilar注射用SHR-A1201trastuzumab emtansine biosimilar (Jiangsu Hengrui Medicine)SHR-A1201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionTubulin inhibitorsAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A